JAK-IN-31 - Search Results | AbMole BioScience

About 6 results found for searched term "JAK-IN-31" (0.125 seconds)

Cat.No.	Name	Target
M41701	JAK-IN-31	JAK
	JAK-IN-31 is a JAK inhibitor with IC50 ranges of ≤0.01µM, ≤0.01µM, 0.01-0.1 µM and ≤0.01µM for JAK1, JAK2, JAK3 and Tyk2 respectively.
M28015	Ilginatinib hydrochloride	JAK
	NS-018 hydrochloride
	Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).
M28016	Ilginatinib	JAK
	NS-018
	Ilginatinib (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).
M28231	Ilginatinib maleate	JAK
	NS-018 maleate
	Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).
M40998	Compound 25ap	HDAC
	Compound 25ap is a potent HDAC/JAK/BRD4 triple inhibitor designed based on the novel multi-targeted HDAC inhibitor Fedratinib, which promotes the hyperacetylation of histones and α-microtubulin, hypophosphorylation of STAT3, and down-regulation of LIFR, MCL-1, and c-Myc in MDA-MB-231 cells, and possesses antitumor activity.
M49636	ZT55	JAK
	ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM.